EyePoint

Q2 FY2026 EarningsEYPT Q2 FY2026 results reflected a mixed performance relative to consensus: revenue of $0.51M beat the $0.37M expected, but net loss was significantly wider than anticipated, with GAAP EPS of -$1.09 missing the -$0.96 consensus. The variance was primarily driven by accelerated R&D spending for Phase 3 trials of DURAVYU, which pushed operating expenses to $97.9M. The company maintains a sufficient cash runway of $180M into Q4 2027, with high-stakes Phase 3 LUGANO data expected in August 2026.